An Open-Label Treatment Investigational New Drug (IND) for the Use of Generex Oral-lyn in Patients With Type 1 or Type 2 Diabetes Mellitus.

Trial Profile

An Open-Label Treatment Investigational New Drug (IND) for the Use of Generex Oral-lyn in Patients With Type 1 or Type 2 Diabetes Mellitus.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2013

At a glance

  • Drugs Insulin (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Generex Biotechnology Corporation
  • Most Recent Events

    • 19 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Jan 2011 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 05 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top